- Twelve abstracts and two late-breaking presentations
demonstrate AbbVie and Allergan Aesthetics' shared commitment to
advancing research across a spectrum of dermatologic conditions and
aesthetic indications
NORTH CHICAGO, Ill.,
March 21, 2022 /PRNewswire/ -- AbbVie
(NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today
announced they will present 12 abstracts and two late-breaking
presentations during the 2022 American Academy of Dermatology (AAD)
Annual Meeting, March 25-29, in
Boston. Data across AbbVie and
Allergan's diversified portfolio of medical and aesthetic
dermatology products underscore the companies' deep-rooted
commitment to advancing science and striving to redefine the
standards of patient care.
AbbVie will present new research on the efficacy, durability and
safety of RINVOQ® (upadacitinib) and SKYRIZI®
(risankizumab-rzaa). Notable data will include a post-hoc analysis
from the Heads Up study evaluating the degree and
distribution of skin improvement from baseline with RINVOQ versus
DUPIXENT® (dupilumab) in adults with moderate to severe
atopic dermatitis. Additionally, AbbVie will present an interim
analysis from the LIMMitless open-label extension trial
investigating continuous SKYRIZI treatment beyond 4.5 years in
adults with moderate to severe plaque psoriasis, as well as new
real-world findings from the CorEvitas Psoriasis Registry,
including patient reported outcomes with SKYRIZI in adults with
moderate to severe plaque psoriasis.
"We look forward to presenting data at AAD that demonstrate
our leadership in and commitment to advancing research across a
myriad of dermatologic conditions," said Celine Goldberger, M.D., vice president, head of
U.S. medical affairs, AbbVie. "Science is at the core of our work,
helping us in our commitment to improve the care of patients with
serious immune-mediated conditions now and for years to come."
Allergan Aesthetics has one of the most researched portfolios in
the aesthetics industry and will spotlight a novel hydrating serum.
Additionally, the company will share results from a multicenter and
randomized controlled study evaluating the safety and effectiveness
of hyaluronic acid (HA) injectable gel for restoring jawline
definition as well as data on the effectiveness and safety of
onabotulinumtoxinA for the treatment of masseter muscle
prominence.
"Our research and development team is focused on driving
innovation to provide the most comprehensive, science-based product
offerings that will continue to help advance aesthetic medicine,"
said Darin Messina, senior vice
president, Allergan Aesthetics R&D. "We are proud to share our
learnings and engage with the larger medical community at AAD."
AbbVie and Allergan Aesthetics abstracts at AAD 2022
include:
Abstract
Title
|
Presentation
Details
(All Times ET)
|
Atopic
Dermatitis
|
Targeted Combined
Endpoint Improvement in Patient and Disease Domains in Atopic
Dermatitis (AD) Among Adults with Moderate-to-Severe AD Treated
with Upadacitinib
|
E-poster
|
Achieving
Incrementally Greater Skin Improvement Thresholds with Upadacitinib
versus Dupilumab in Moderate-to-Severe Atopic Dermatitis (AD):
Heads Up Study Results
|
E-poster
|
Psoriasis
|
Long-Term Efficacy
and Safety of Risankizumab for the Treatment of Moderate to Severe
Plaque Psoriasis: Interim Analysis of Results from the LIMMitless
Open-Label Extension Trial Beyond 4 Years of Follow
Up
|
Poster with Oral;
March 27, 2022,
9:50-9:55 a.m.
|
Long-Term Safety of
Risankizumab in Patients with Psoriatic Disease: Findings from
Integrated Analyses of 17 Clinical Trials in Psoriasis and 4 in
Psoriatic Arthritis
|
Poster with Oral;
March 27, 2022,
11:45-11:50 a.m.
|
Real-World
Patient-Reported Outcomes with Risankizumab in Patients with
Moderate to Severe Psoriasis from CorEvitas Psoriasis
Registry
|
Poster with Oral;
March 27, 2022,
11:50-11:55 a.m.
|
Real-World
Treat-To-Target Skin Clearance with Risankizumab in Patients with
Moderate to Severe Psoriasis from the CorEvitas Psoriasis
Registry
|
E-poster
|
Psoriatic
Arthritis
|
Impact of
Risankizumab on Improving Health-Related Quality of Life, Work
Productivity, and Reducing Fatigue Among Patients with Active
Psoriatic Arthritis: A Pooled Analysis of Two Phase 3 Clinical
Trials
|
Poster with Oral;
March 27, 2022,
8:30-8:35 a.m.
|
Effects of Treatment
with Risankizumab on Reducing Pain and Inflammation in Patients
with Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2
Trials
|
Poster with Oral;
March 27, 2022,
9:10-9:15 a.m.
|
Impact of
Risankizumab on Achieving Minimal Clinically Important Differences
in Patient-Reported Disease Activity, Fatigue and Pain Among
Patients with Active Psoriatic Arthritis: Analysis of Two Phase 3
Clinical Trials
|
Poster with Oral;
March 27, 2022,
4:30-4:35 p.m.
|
Impact of
Risankizumab on Improving Symptoms and Health-Related Quality of
Life and Reducing Fatigue and Pain Among Psoriatic Arthritis
Patients with Moderate to Severe Skin Involvement: Evidence from
Two Phase III Trials
|
E-poster
|
Aesthetics
|
Efficacy and Safety
of 2 Doses of OnabotulinumtoxinA for the Treatment of Masseter
Muscle Prominence: 6-Month Results from a Randomized, Phase 2b
Placebo-Controlled Study
|
E-poster
|
Restoring Jawline
Definition with the Hyaluronic Acid Injectable Gel VYC-25L: Results
from a Pivotal, Multicenter, Randomized Controlled
Study
|
Late-breaking
Poster
with Oral;
March 26, 2022,
1:10-1:20 p.m.
|
Improvement in Skin
Quality with a Cosmetic Hydrating Serum Delivered via Diamond Tip
Microdermabrasion Combined with Topical Daily Serum
|
Late-breaking
Poster
with Oral;
March 26, 2022,
2:50-3:00 p.m.
|
Mechanism for
Improvement in the Appearance of Skin Laxity Resulting from a
Single Treatment with Acoustic Subcision: Induction of New Collagen
(Type III) and Elastin
|
E-poster
|
SKYRIZI is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading development and commercialization
of SKYRIZI globally.
The 2022 AAD Annual Meeting e-Posters will be available here and
late-breaking sessions will be available here.
About RINVOQ® (upadacitinib)
Discovered and
developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor
that is being studied in several immune-mediated inflammatory
diseases.1 Based on enzymatic and cellular assays,
RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2,
JAK-3, and TYK-2.2 The relevance of inhibition of
specific JAK enzymes to therapeutic effectiveness and safety is not
currently known.
In the U.S., RINVOQ is approved for the treatment of adults
with moderately to severely active rheumatoid arthritis who have
had an inadequate response or intolerance to one or more TNF
blockers as well as adults with active psoriatic arthritis who have
had an inadequate response or intolerance to one or more TNF
blockers.2 RINVOQ is approved for use in adults and
pediatric patients 12 years of age and older with refractory,
moderate to severe atopic dermatitis whose disease is not
adequately controlled with other systemic drug products, including
biologics, or when use of those therapies are inadvisable. RINVOQ
is approved for the treatment of adults with moderately to severely
active ulcerative colitis who have had an inadequate response or
intolerance to one or more TNF blockers. In the EU, RINVOQ is
approved for the treatment of adults with moderate to severe active
rheumatoid arthritis, adults with active psoriatic arthritis and
adults with active ankylosing spondylitis. RINVOQ is also approved
in the EU for adults and adolescents with moderate to severe atopic
dermatitis.
Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic
dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's
disease, ulcerative colitis, giant cell arteritis and Takayasu
arteritis are ongoing.3-10
RINVOQ® (upadacitinib) U.S. Use and
Important Safety Information2
RINVOQ is a prescription medicine used:
- To treat adults with moderate to severe rheumatoid
arthritis when 1 or more medicines called tumor necrosis
factor (TNF) blockers have been used, and did not work well or
could not be tolerated.
- To treat adults with active psoriatic
arthritis when 1 or more medicines called TNF blockers
have been used, and did not work well or could not be
tolerated.
- To treat adults with moderately to severely active
ulcerative colitis when 1 or more medicines called TNF
blockers have been used, and did not work well or could not be
tolerated.
It is not known if RINVOQ is safe and effective in children with
juvenile idiopathic arthritis, psoriatic arthritis, or with
ulcerative colitis.
- To treat adults and children 12 years of age and older with
moderate to severe eczema (atopic dermatitis) that did not
respond to previous treatment and their eczema is not well
controlled with other pills or injections, including biologic
medicines, or when the use of other pills or injections is not
recommended.
RINVOQ is safe and effective in children 12 years of age and
older weighing at least 88 pounds (40 kg) with atopic
dermatitis.
It is not known if RINVOQ is safe and effective in children
under 12 years of age with atopic dermatitis.
What is the most important information I should know about
RINVOQ?
RINVOQ may cause serious side effects, including:
- Serious infections. RINVOQ can lower your ability
to fight infections. Serious infections have happened while taking
RINVOQ, including tuberculosis (TB) and infections caused by
bacteria, fungi, or viruses that can spread throughout the body.
Some people have died from these infections. Your healthcare
provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment
with RINVOQ. You should not start taking RINVOQ if you have any
kind of infection unless your HCP tells you it is okay. If you get
a serious infection, your HCP may stop your treatment until your
infection is controlled. You may be at higher risk of developing
shingles (herpes zoster).
- Increased risk of death in people 50 years and older who
have at least 1 heart disease (cardiovascular) risk
factor.
- Cancer and immune system problems. RINVOQ may increase
your risk of certain cancers. Lymphoma and other cancers, including
skin cancers, can happen. Current or past smokers are at higher
risk of certain cancers, including lymphoma and lung cancer. Follow
your HCP's advice about having your skin checked for skin cancer
during treatment with RINVOQ. Limit the amount of time you spend in
sunlight. Wear protective clothing when you are in the sun and use
sunscreen.
- Increased risk of major cardiovascular (CV) events, such as
heart attack, stroke, or death, in people 50 years and older who
have at least 1 heart disease (CV) risk factor, especially if you
are a current or past smoker.
- Blood clots: Blood clots in the veins of the legs
or lungs and arteries can happen with RINVOQ. This may be
life-threatening and cause death. Blood clots in the veins of the
legs and lungs have happened more often in people who are 50 years
and older and with at least 1 heart disease (CV) risk factor.
- Allergic reactions. Symptoms such as rash (hives),
trouble breathing, feeling faint or dizzy, or swelling of your
lips, tongue, or throat, that may mean you are having an allergic
reaction have been seen in people taking RINVOQ. Some of these
reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical
help right away.
- Tears in the stomach or intestines and changes in certain
laboratory tests. Your HCP should do blood tests before
you start taking RINVOQ and while you take it. Your HCP may stop
your RINVOQ treatment for a period of time if needed because of
changes in these blood test results.
Do not take RINVOQ if:
- You are allergic to upadacitinib or any of the ingredients
in RINVOQ.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
- Are being treated for an infection, have an infection that
won't go away or keeps coming back, or have symptoms of an
infection such as:
-
- Fever, sweating, or chills
- Shortness of breath
- Warm, red, or painful skin or sores on your body
- Muscle aches
- Feeling tired
- Blood in phlegm
- Diarrhea or stomach pain
- Cough
- Weight loss
- Burning when urinating or urinating more often than normal
- Have TB or have been in close contact with someone with
TB.
- Are a current or past smoker.
- Have had a heart attack, other heart problems, or stroke.
- Have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), blood clots in the veins of your legs or
lungs, diverticulitis (inflammation in parts of the large
intestine), or ulcers in your stomach or intestines.
- Have other medical conditions including liver problems, low red
or white blood cell counts, diabetes, chronic lung disease,
HIV, or a weak immune system.
- Live, have lived, or have traveled to parts of the country,
such as the Ohio and Mississippi River valleys and the
Southwest, that increase your risk of getting certain kinds of
fungal infections. If you are unsure if you've been to these types
of areas, ask your HCP.
- Have recently received or are scheduled to receive a vaccine.
People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on findings in
animal studies, RINVOQ may harm your unborn baby. Your HCP will
check whether or not you are pregnant before you start RINVOQ. You
should use effective birth control (contraception) to avoid
becoming pregnant during treatment with RINVOQ and for 4 weeks
after your last dose.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into
your breast milk. Do not breastfeed during treatment with
RINVOQ and for 6 days after your last dose.
Tell your HCP about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system
If you are not sure if you are taking any of these medicines,
ask your HCP or pharmacist.
What should I do or tell my HCP AFTER starting
RINVOQ?
- Tell your HCP right away if you have any symptoms of an
infection. RINVOQ can make you more likely to get infections or
make any infections you have worse
- Get emergency help right away if you have any symptoms of a
heart attack or stroke while taking RINVOQ, including:
-
- Discomfort in the center of your chest that lasts for more than
a few minutes or that goes away and comes back
- Severe tightness, pain, pressure, or heaviness in your chest,
throat, neck, or jaw
- Pain or discomfort in your arms, back, neck, jaw, or
stomach
- Shortness of breath with or without chest discomfort
- Breaking out in a cold sweat
- Nausea or vomiting
- Feeling lightheaded
- Weakness in one part or on one side of your body
- Slurred speech
- Tell your HCP right away if you have any signs or symptoms of
blood clots during treatment with RINVOQ, including:
-
- Swelling
- Pain or tenderness in one or both legs
- Sudden unexplained chest or upper back pain
- Shortness of breath or difficulty breathing
- Tell your HCP right away if you have a fever or stomach-area
pain that does not go away, and a change in your bowel habits.
What are the common side effects of RINVOQ?
These include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus
infections (including cold sores), bronchitis, nausea, cough,
fever, acne, headache, increased blood levels of creatine
phosphokinase, allergic reactions, inflammation of hair follicles,
stomach-area (abdominal) pain, increased weight, flu, tiredness,
lower number of certain types of white blood cells (neutropenia,
lymphopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, and increased liver enzyme levels.
Separation or tear to the lining of the back part of the eye
(retinal detachment) has happened in people with atopic dermatitis
treated with RINVOQ. Call your HCP right away if you have any
sudden changes in your vision during treatment with RINVOQ.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split,
crush, or chew the tablet. Take RINVOQ exactly as your HCP tells
you to use it. RINVOQ is available in 15 mg, 30 mg and 45 mg
extended-release tablets.
This is the most important information to know about RINVOQ.
For more information, talk to your HCP.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit http://www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn
more.
Please click here for the Full Prescribing
Information and Medication Guide.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively
blocks IL-23 by binding to its p19 subunit.11 IL-23, a
cytokine involved in inflammatory processes, is thought to be
linked to a number of chronic immune-mediated diseases, including
psoriasis.11 SKYRIZI is approved in the U.S. to treat
moderate to severe plaque psoriasis in adults who are candidates
for systemic therapy or phototherapy, as well as to treat active
psoriatic arthritis in adults. In the EU, SKYRIZI is indicated for
the treatment of moderate to severe plaque psoriasis in adults who
are candidates for systemic therapy. SKYRIZI, alone or in
combination with methotrexate (MTX), is indicated for the treatment
of active psoriatic arthritis in adults who have had an inadequate
response or who have been intolerant to one or more
disease-modifying antirheumatic drugs (DMARDs). The approved dose
for SKYRIZI is 150 mg (one 150 mg pre-filled pen or pre-filled
syringe) administered by subcutaneous injection at week 0 and 4,
and every 12 weeks thereafter. Phase 3 trials of SKYRIZI in
psoriasis, Crohn's disease, ulcerative colitis and psoriatic
arthritis are ongoing.12-20
SKYRIZI U.S. Uses and Important Safety
Information21
SKYRIZI is a prescription
medicine used to treat adults with:
- Moderate to severe plaque psoriasis who may benefit from taking
injections or pills (systemic therapy) or treatment using
ultraviolet or UV light (phototherapy).
- Active psoriatic arthritis (PsA).
What is the most important information I should know about
SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medication that may cause serious
side effects, including:
Serious Allergic
Reactions:
- Stop using SKYRIZI and get emergency help right away if you get
any of the following symptoms of serious allergic reaction:
-
- Fainting, dizziness, feeling lightheaded (low blood
pressure)
- Swelling of your face, eyelids, lips, mouth, tongue, or
throat
- Trouble breathing or throat tightness
- Chest tightness
- Skin rash, hives
- Itching
Infections:
SKYRIZI may lower the ability of
your immune system to fight infections and may increase your risk
of infections. Your healthcare provider should check you for
infections and tuberculosis (TB) before starting treatment with
SKYRIZI and may treat you for TB before you begin treatment with
SKYRIZI if you have a history of TB or have active TB. Your
healthcare provider should watch you closely for signs and symptoms
of TB during and after treatment with SKYRIZI.
- Tell your healthcare provider right away if you have an
infection or have symptoms of an infection, including:
-
- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from
your psoriasis
- diarrhea or stomach pain
- shortness of breath
- blood in your mucus (phlegm)
- burning when you urinate or urinating more often than
normal
Do not use SKYRIZI if you are allergic to
risankizumab-rzaa or any of the ingredients in SKYRIZI.
Before using SKYRIZI, tell your healthcare provider about all
of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section
"What is the most important information I should know about
SKYRIZI?"
- have an infection that does not go away or that keeps coming
back.
- have TB or have been in close contact with someone with
TB.
- have recently received or are scheduled to receive an
immunization (vaccine). Medications that interact with the immune
system may increase your risk of getting an infection after
receiving live vaccines. You should avoid receiving live vaccines
right before, during, or right after treatment with SKYRIZI. Tell
your healthcare provider that you are taking SKYRIZI before
receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if
SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
SKYRIZI passes into your breast milk.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most
important information I should know about SKYRIZI?"
The most common side effects of SKYRIZI include upper
respiratory infections, feeling tired, fungal skin infections,
headache, and injection site reactions.
These are not all the possible side effects of SKYRIZI. Call
your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use
it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and
pen.
This is not a complete summary of all safety
information.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit http://www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn
more.
Please click here for Full Prescribing
Information and Medication
Guide for SKYRIZI.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
IMPORTANT SAFETY INFORMATION & APPROVED
USES
BOTOX® Cosmetic may
cause serious side effects that can be life threatening. Get
medical help right away if you have any of these problems any time
(hours to weeks) after injection of BOTOX®
Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakness of
associated muscles can be severe and result in a loss of life. You
are at the highest risk if these problems are pre-existing before
injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may
affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same
as, or comparable to, any other botulinum toxin product. There
has not been a confirmed serious case of spread of toxin effect
when BOTOX® Cosmetic has been used at the
recommended dose to treat frown lines, crow's feet lines, and/or
forehead lines. BOTOX® Cosmetic may cause loss of
strength or general muscle weakness, vision problem, or dizziness
within hours to weeks of taking BOTOX® Cosmetic. If
this happens, do not drive a car, operate machinery, or do other
dangerous activities.
Serious and/or immediate allergic reactions have been
reported. They include: itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you are wheezing or have asthma
symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are
allergic to any of the ingredients in BOTOX® Cosmetic
(see Medication Guide for ingredients); had an allergic reaction to
any other botulinum toxin product such as Myobloc®
(rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin infection at
the planned injection site.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions,
including: plans to have surgery; had surgery on your face;
have trouble raising your eyebrows; drooping eyelids; any other
abnormal face change; are pregnant or plan to become pregnant (it
is not known if BOTOX® Cosmetic can harm your unborn
baby); are breast-feeding or plan to (it is not known if
BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. Using BOTOX® Cosmetic with certain
other medicines may cause serious side effects. Do not start any
new medicines until you have told your doctor that you have
received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections or botulinum
toxin such as Myobloc®, Dysport®, or
Xeomin® in the past (tell your doctor exactly which
product you received); have recently received an antibiotic by
injection; take muscle relaxants, take an allergy or cold medicine;
take a sleep medicine; take aspirin-like products or blood
thinners.
Other side effects of BOTOX® Cosmetic include:
dry mouth, discomfort or pain at the injection site; tiredness;
headache; neck pain; and eye problems: double vision, blurred
vision, decreased eyesight, drooping eyelids and eyebrows, swelling
of your eyelids and dry eyes.
APPROVED USES
BOTOX® Cosmetic is a
prescription medicine that is injected into muscles and used to
temporarily improve the look of moderate to severe forehead lines,
crow's feet lines, and frown lines between the eyebrows in
adults.
For more information refer to the Medication Guide or talk with
your doctor.
To report a side effect, please call Allergan at
1-800-678-1605.
Please see BOTOX Cosmetic full Product
Information including Boxed Warning and Medication Guide.
DiamondGlow® Uses
The
DiamondGlow® device is a general dermabrasion
device that gently removes the top layer of skin and delivers
topical cosmetic serums onto the skin.
DiamondGlow® Important Safety
Information
The DiamondGlow® treatment is not for
everyone. You should not have a DiamondGlow® treatment
if you have compromised skin quality. Tell your provider if you are
pregnant or lactating, or if you have medical condition, including
allergies, and if you are using topical medications on the area to
be treated.
Typical side effects include a scratchy, stinging sensation
during the treatment and temporary tightness, redness or slight
swelling after the treatment. Rare serious side effects may also
occur and include severe skin irritation and allergic
reactions.
SkinMedica® Pro-Infusion Serums
Disclaimer
SkinMedica® Pro-Infusion Serums are
intended to meet the FDA's definition of a cosmetic product, an
article applies to the human body to cleanse, beautify, promote
attractiveness, and alter appearances. These products are not
intended to be drugs that diagnose, treat, cure, or prevent any
disease or condition. These products have not been approved by the
FDA and the statements have not been evaluated by the FDA.
RESONIC™ Important Safety Information RESONIC™
(Rapid Acoustic Pulse™ device) is indicated for use as an accessory
to the 1064 nm Q-Switched laser for black ink tattoo removal in
Fitzpatrick Skin Type I-III patients. The RESONIC device is also
indicated for long-term improvement in the appearance of cellulite
as supported by clinical data demonstrating treatment benefits up
to 1 year of observation. The most common side effects may include
mild to moderate temporary redness of the treatment site, mild
pain, heat, and pinpoint redness. Your results and experience may
vary, so it is important to talk to your healthcare provider about
whether RESONIC is right for you. For full safety information,
please visit www.RESONIC.com/ISI.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines that solve serious health issues today
and address the medical challenges of tomorrow. We strive to have a
remarkable impact on people's lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women's health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us at www.abbvie.com.
Follow @abbvie on
Twitter, Facebook, LinkedIn or Instagram.
About Allergan Aesthetics
Allergan Aesthetics, an
AbbVie company, develops, manufactures, and markets a portfolio of
leading aesthetics brands and products. Their aesthetics
portfolio includes facial injectables, body contouring, plastics,
skin care, and more. Their goal is to consistently provide
customers worldwide with innovation, education, exceptional
service, and a commitment to excellence, all with a personal
touch. www.AllerganAesthetics.com
AbbVie Forward-Looking Statements
Some statements
in this news release are, or may be considered, forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. The words "believe," "expect," "anticipate," "project"
and similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits from AbbVie's acquisition of Allergan plc
("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2021 Annual Report on Form 10-K, which has
been filed with the Securities and Exchange Commission, as updated
by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes
no obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
References:
- Pipeline – Our Science | AbbVie. AbbVie. 2019. Available at:
https://www.abbvie.com/our-science/pipeline.html. Accessed on
March 8, 2022.
- RINVOQ (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
- A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults
With Rheumatoid Arthritis on a Stable Dose of Conventional
Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have
an Inadequate Response to csDMARDs Alone (SELECT-NEXT).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02675426. Accessed on
March 8, 2022.
- Evaluation of Upadacitinib in Adolescent and Adult Patients
With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03569293. Accessed on
March 8, 2022.
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to
Adalimumab in Participants With Psoriatic Arthritis Who Have an
Inadequate Response to at Least One Non-Biologic Disease Modifying
Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03104400.
Accessed on March 8, 2022.
- A Study to Evaluate Efficacy and Safety of Upadacitinib in
Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04169373. Accessed on
March 8, 2022.
- A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in
Participants With Moderately to Severely Active Crohn's Disease Who
Have Inadequately Responded to or Are Intolerant to Biologic
Therapy. ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03345836. Accessed on
Accessed on March 8, 2022.
- A Study to Evaluate the Safety and Efficacy of Upadacitinib
(ABT-494) for Induction and Maintenance Therapy in Participants
With Moderately to Severely Active Ulcerative Colitis (UC).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on
March 8, 2022.
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in
Participants With Giant Cell Arteritis (SELECT-GCA).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on
March 8, 2022.
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in
Subjects With Takayasu Arteritis (TAK) (SELECT-TAK).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04161898. Accessed on
March 8, 2022.
- Duvallet E., Sererano L., Assier E., et al. Interleukin-23: a
key cytokine in inflammatory diseases. Ann Med. 2011. Nov
43(7):503-11.
- BI 655066 (Risankizumab) Compared to Placebo and Active
Comparator (Ustekinumab) in Patients With Moderate to Severe
Chronic Plaque Psoriasis. ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02684370. Accessed on
March 8, 2022.
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab)
in Patients With Moderate to Severe Chronic Plaque Psoriasis.
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02684357. Accessed on
March 8, 2022.
- BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe
Plaque Psoriasis With Randomized Withdrawal and Re-treatment.
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02672852. Accessed on
March 8, 2022.
- BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator
(Adalimumab) in Patients With Moderate to Severe Chronic Plaque
Psoriasis. ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02694523. Accessed on
March 8, 2022.
- A Study of the Efficacy and Safety of Risankizumab in
Participants With Moderately to Severely Active Crohn's Disease.
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03105128. Accessed on
March 8, 2022.
- A Study to Assess the Efficacy and Safety of Risankizumab in
Participants With Ulcerative Colitis. ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03398135.
Accessed on March 8, 2022.
- A Multicenter, Randomized, Double-Blind, Placebo Controlled
Induction Study to Evaluate the Efficacy and Safety of Risankizumab
in Participants With Moderately to Severely Active Ulcerative
Colitis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03398148. Accessed on
March 8, 2022.
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients
With Active Psoriatic Arthritis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03675308. Accessed on
March 8, 2022.
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients
With Active Psoriatic Arthritis. Available at:
https://clinicaltrials.gov/ct2/show/NCT03671148. Accessed on
March 8, 2022.
- SKYRIZI (risankizumab) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
View original
content:https://www.prnewswire.com/news-releases/abbvie-and-allergan-aesthetics-to-present-new-research-across-dermatology-portfolio-at-2022-aad-annual-meeting-301506280.html
SOURCE AbbVie